Charles River Labs的战略审查和董事会变动使其存货增加了22%,尽管年均产量下降了25.5%。 Charles River Labs' strategic review and board changes boosted its stock by 22%, despite a 25.5% YTD decline.

Charles River实验室宣布了一项战略审查和董事会变动,导致22%的库存激增。 Charles River Laboratories announced a strategic review and board changes, leading to a 22% stock surge. 该公司更新了其FY25展望,预测收入为每股4.35美元至4.85美元,调整后的收益为每股9.30美元至9.80美元,收入略有下降,原因是其每日生活津贴部分的净订票量有所改善。 The company updated its FY25 outlook, projecting earnings of $4.35 to $4.85 per share and adjusted earnings of $9.30 to $9.80 per share, on a slightly declining revenue due to improved net bookings in its DSA segment. 尽管库存量有所增加,但目前仍然下降25.5%。 Despite the stock increase, it is still down 25.5% year-to-date.